36 results about "TB bacillus" patented technology

The present invention discloses a compound with structural formula I. The compound of the present invention exhibits strong inhibitory activity against Mycobacterium tuberculosis, has good antituberculosis effects, and has a significantly reduced MIC value compared with isoniazid, a first-line clinical drug. It has weak inhibitory effects on the proliferation of human hepatoma cells HepG2 and Chang cells and has good safety. In addition, in the experiment of Mycobacterium tuberculosis infection overexpressing DprE1, the antibacterial ability of the compound decreased, further verifying that the compound exerts its antibacterial effect by inhibiting the DprE1 enzyme, and it is a novel DprE1 inhibitor.

The invention provides a mycobacterium tuberculosis rapid detection system based on digital CRISPR-Cas polydispersion liquid drops, the rapid detection system does not comprise a PCR amplification detection device, the system comprises a nucleic acid extraction subsystem, the nucleic acid extraction subsystem is used for heating a mycobacterium tuberculosis sample to be detected by using a PBS buffer solution containing dithiothreitol, and the nucleic acid extraction subsystem is used for extracting nucleic acid from the mycobacterium tuberculosis sample to be detected. Extracting mycobacterium tuberculosis DNA in a sample to be detected; a polydispersion liquid drop generation subsystem and a polydispersion liquid drop detection subsystem. The rapid detection system disclosed by the invention realizes on-site amplification-free detection of tubercle bacillus by combining rapid extraction of tubercle bacillus nucleic acid and a digital CRISPR technology.

The invention discloses a novel compound preparation for resisting mycobacterium tuberculosis and a preparation method thereof.The compound preparation comprises glutathione active part and pyrazinamide, the weight ratio of glutathione to pyrazinamide is (2-4): 5, the glutathione active part comprises glutathione, an isolation stabilizer, a plasticizer, an anti-sticking agent and a first stabilizer, and the first stabilizer comprises glutathione, an isolation stabilizer, a plasticizer, an anti-sticking agent and a second stabilizer. According to the glutathione active part, firstly, a fluidized powder coating technology is adopted, and the relatively unstable active ingredient glutathione is subjected to powder coating; and preparing the coated components, pyrazinamide, a filler, a second stabilizer, an adhesive, a disintegrating agent and a lubricant into a specific preparation. According to the preparation, the hepatotoxicity during pyrazinamide medication is reduced, the compliance is increased, and meanwhile, the technical problem that a pyrazinamide glutathione preparation is unstable is solved.

The present invention discloses a kit and a detection method for detecting gene mutation sites based on fluorescent quantitative PCR using a lock ring probe. The present invention combines the lock ring probe ligation technology in RCA technology with real-time fluorescent quantitative PCR technology, utilizes the lock ring probe ligation characteristics to detect point mutations, and utilizes qPCR technology to achieve signal amplification with high sensitivity and good specificity. It has been used to detect the T478K mutation site of the SARS-cov2-Delta mutant strain, the CD17 mutation site of thalassemia, and the 531 mutation site of the rpoB gene of the rifampicin-resistant strain of Mycobacterium tuberculosis; wherein the minimum detection limit of SARS-cov2 can reach 54.9fM, and the detection limits of thalassemia and tuberculosis resistance are 95.35zM and 55.12aM, respectively. This method can also be widely used in the detection of gene mutation sites related to other diseases.

The application discloses a mycobacterium tuberculosis tandem DNA vaccine W545 and a preparation method and application thereof. The application constructs a novel mycobacterium tuberculosis DNA vaccine W545 with a multi-antigen immune dominant epitope by connecting epitope genes of Ag85A protein and Ag85B protein antigen and Rv1419, Rv3407 and Rv2628c together in series through genetic engineering technology and connecting the epitope genes to a eukaryotic expression vector pVAX1. The prepared mycobacterium tuberculosis tandem DNA vaccine W545 can significantly enhance specific cellular immune function of mice, mainly stimulates Th1 type immune response, and can make the lesion range of organs and tissues of a mouse tuberculosis model significantly reduced and the lesion alleviated in treatment, and can be used in preparation of drugs or vaccines for preventing or treating tuberculosis.

The invention discloses a method for rapidly detecting intracellular mycobacterium tuberculosis, which comprises the following steps: marking mycobacterium tuberculosis by using mScarlet, marking host cells by CFSE, rinsing part of extracellular bacteria which do not enter macrophages by PBS and sterilizing by gentamicin, detecting the survival amount of the intracellular mycobacterium tuberculosis by using a flow cytometer, and completing sample analysis within several hours. The experimental period is remarkably shortened, the research efficiency is improved, and the method is suitable for large-scale sample analysis.

The invention discloses a micromolecule polypeptide capable of inhibiting intracellular survival of mycobacterium tuberculosis and application of the micromolecule polypeptide, and belongs to the technical field of biology. The amino acid sequence of the micromolecule polypeptide is VLARYASICQ (SEQ ID NO.1), and the micromolecule polypeptide has cell penetrability, can promote glycolysis, and further inhibits the survival of mycobacterium tuberculosis in macrophages and mice. The micromolecule polypeptide can be used for preparing a medicine for resisting mycobacterium tuberculosis infection. The results of the invention can provide new tools and ideas for clinical prevention and treatment of tuberculosis, and especially have broad prospects in the aspects of development, clinical application and the like of anti-tuberculosis drugs. The invention has important application value for obtaining novel antituberculosis drugs.

This invention belongs to the field of traditional Chinese medicine oral decoction preparation technology. Specifically, it relates to a method for preparing a stable and safe decoction of traditional Chinese medicine composition for hepatitis, jaundice virus, cirrhosis, and ascites. The decoction is prepared by decocting the following eleven traditional Chinese medicine components: 30g of raw Lysimachia christinae, 30g of Plantago asiatica, 30g of Poria cocos peel, 30g of Dioscorea opposita, 26g of Areca catechu peel, 16g of Salvia miltiorrhiza, 16g of Bupleurum chinense, 16g of Alisma plantago-aquatica, 16g of Astragalus membranaceus, 13g of Lycopus lucidus, and 10g of processed pangolin scales. When decocting, pour the mixture into a sterilized and cleaned porcelain medicine pot, add cold water and soak for 30 minutes. Bring to a boil over high heat, then simmer over low heat for 20 minutes. Turn off the heat and let it cool slightly before drinking. This is the medicine product. By combining classical traditional methods with modern decoction technology, the decoction of these eleven traditional Chinese medicines yields a traditional Chinese medicine preparation with significant effects and convenient administration. This formula features comprehensive regulation and enhancement. It selects herbs such as Lysimachia christinae, Plantago asiatica, Poria cocos, and Salvia miltiorrhiza, which have antibacterial, drainage, dampness-removing, anti-inflammatory, and blood-stasis-removing components for liver ascites. The combination of eleven Chinese herbs has anti-inflammatory, detoxifying, and dampness-removing effects, which are beneficial for treating liver ascites lesions, removing hepatitis, jaundice, tuberculosis, damp-heat accumulation, inflammation-induced ascites, enhancing immunity, and healing effects.

The present invention relates to a novel antituberculosis engineered protein and, more specifically, to an antituberculosis use of a human tryptophanyl-tRNA synthesis 1-based engineered protein comprising one or more amino acid mutations. The engineered protein according to the present invention has high thermal stability and has the effect of significantly inhibiting the growth of Mycobacterium tuberculosis. In addition, it has been experimentally identified that the engineered protein of the present invention promotes penetration of immune cells into tissue. The engineered protein of the present invention has excellent antituberculosis efficacy and immune enhancement efficacy, and thus can be variously utilized in the fields of tuberculosis treatment and immune enhancement.

The present application provides an anti-tuberculosis drug and a preparation method and application thereof. Specifically, the present application provides a compound shown in formula I or an enantiomer, diastereoisomer, solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof and a preparation method and application thereof. The compound of the present application has excellent bacteriostatic activity and can effectively treat diseases related to bacterial infection, especially diseases related to infection of Mycobacterium tuberculosis.

The invention discloses a nucleoside antibiotic with anti-mycobacterium tuberculosis activity and a preparation method and application thereof. The nucleoside antibiotic is muramycin D9 which is extracted and separated from fermentation liquor of streptomyces sp. NRRL 30475, the molecular formula of the nucleoside antibiotic is C38H61N11O15, and the nucleoside antibiotic is a muramycin compound which is obtained by dehydrating and cyclizing valine at the terminal of a peptide chain and non-protein source amino acid epicpremycine imine for the first time. An in-vitro anti-mycobacterium tuberculosis activity research shows that the nucleoside compound provided by the invention has very strong antibacterial activity on mycobacterium smegmatis and is expected to be developed into a novel anti-mycobacterium tuberculosis medicine.

The invention provides a mycobacterium tuberculosis recombinant fusion protein EMC, and the connection sequence of the mycobacterium tuberculosis recombinant fusion protein EMC is as follows: EAST6-MPT64-CFP10. The fusion protein formed by the EAST6 protein, the MPT64 protein and the CFP10 protein has better antigenicity, it is found that effective series connection can more effectively promote mutual complementation of the EAST6 protein, the MPT64 protein and the CFP10 protein in the antigenicity aspect, the number of antigen epitopes is increased, and then the antigenicity of the fusion protein is remarkably improved; and the use dosage of the fusion protein as a detection antigen for immunological diagnosis and an antigen for vaccine development is effectively reduced. The invention also provides a novel tuberculosis intradermal diagnostic reagent and a preparation method thereof.

The invention provides a pharmaceutical composition for preventing and / or treating diseases caused by mycobacterium tuberculosis infection. The pharmaceutical composition contains a substance for inhibiting the activity of Rv2521 protein or a substance for reducing the content of the Rv2521 protein. According to the invention, an Rv2521 large-fragment knockout strain delta Rv2521 is constructed, and a complement strain delta Rv2521:: 2521 is further constructed, compared with cells infected with delta Rv2521, the death rate of the cells infected with the WT or delta Rv2521: 2521 strain is obviously increased, and the intracellular LPO (marker of ferroptosis) level displayed by the cells infected with the WT or delta Rv2521: 2521 strain is obviously higher than that displayed by the cells infected with the delta Rv2521 strain, so that the death rate of the cells infected with the delta Rv2521 strain is obviously increased. The Mtb Rv2521 is a key ferroptosis promoting effector in the mycobacterium tuberculosis infection process, can promote the survival and dissemination of mycobacterium tuberculosis in macrophages, and can provide a new target spot for clinical tuberculosis treatment and antituberculosis drug development.

The invention relates to a mosquito-killing smoke sheet taking folium artemisiae argyi powder as a base material, and belongs to the technical field of manufacturing of smoke mosquito-killing products. The mosquito-repellent incense is prepared from the following raw materials in percentage by weight: 1.8% of tetramethrin, 30% of folium artemisiae argyi powder, 46% of pottery clay powder, 14% of potassium chlorate, 8% of ammonium sulfate, 0.2% of essence and the like. The argil powder is used as a bonding forming raw material, the folium artemisiae argyi powder is used as a combustion base material, other drugs for repelling and killing mosquitoes and flies are matched, mosquitoes and flies can be effectively repelled and killed for a long time, moxa smoke generated after combustion of the folium artemisiae argyi powder has the effects of killing and inhibiting mycobacterium tuberculosis, staphylococcus, adenosine viruses and influenza viruses, and the effects of sterilizing and disinfecting air, preventing plague, preventing diseases and the like are achieved. The transmission of iatrogenic bacteria is reduced, and the cross infection is controlled. Besides, the folium artemisiae argyi powder is used for replacing wood powder to serve as a combustion base material, a large number of wood resources are saved, the cost of raw materials of the mosquito-killing tobacco flake is reduced, folium artemisiae argyi is a compositae plant which is low in planting cost and very good in planting, and farmers can be encouraged to plant folium artemisiae argyi to increase income.

The invention provides a traditional Chinese medicine composition for treating pneumoconiosis complicated with pulmonary tuberculosis and a preparation method thereof. The traditional Chinese medicine composition is prepared from, by weight, 12-15 parts of radix rehmanniae, 6-9 parts of rhizoma picrorhizae, 10-12 parts of radix asparagi, 12-15 parts of radix rehmanniae preparata, 10-12 parts of radix ophiopogonis, 8-10 parts of radix gentianae macrophyllae, 10-15 parts of radix adenophorae, 6-9 parts of rhizoma pini, 9-12 parts of radix scutellariae, 8-10 parts of rhizoma corydalis, 9-12 parts of fritillary bulb, 6-9 parts of sweet wormwood herb, 10-12 parts of colla corii asini, 9-12 parts of rhizoma anemarrhenae, 8-10 parts of mulberry bark, 9-12 parts of rhizoma bletillae, 6-9 parts of September, 8-10 parts of cortex moutan, 6-9 parts of radix notoginseng, 10-12 parts of According to the composition disclosed by the invention, a compound preparation with a synergistic treatment effect is formed through scientific compatibility of multiple traditional Chinese medicinal materials. According to the invention, radix rehmanniae and radix rehmanniae preparata are used as monarch drugs to nourish yin and blood; radix asparagi, radix ophiopogonis and adenophora stricta are used as ministerial drugs to enhance the effect of moistening the lung; radix scutellariae, rhizoma anemarrhenae, mulberry bark and the like are used for clearing heat and eliminating phlegm; and the liquorice is used for harmonizing the medicines. All the components have a synergistic effect according to a specific proportion, and the traditional Chinese medicine can improve pneumoconiosis fibrosis and inhibit mycobacterium tuberculosis, so that the effect of treating both symptoms and root causes is achieved.

The invention relates to a micro-fluidic chip for detecting urinary sediment, an intelligent dyeing detection device and an intelligent dyeing method. The device has the advantages that the fluid mechanics principle of urine particles is utilized, the micro-column array is designed, high-adhesion treatment is combined, capillary channel movement is utilized, the fluid movement direction of urine sediment passing through the micro-column arrays with different sizes and densities is controlled on the microscale, urine sediment components with different particle sizes and different forms are separated, and the urine sediment separation effect is achieved. Non-invasive intelligent separation of particles in urine liquid and enrichment of visible components in different chip positions are realized; the enrichment and concentration of urine cells of an ultra-large urine sample volume (greater than 100ml) are automatically realized, the detection rate of microorganisms such as tumor cells and mycobacterium tuberculosis is greatly improved, and the situation that a small sample detection result cannot represent the real urinary sediment characteristics of a patient is avoided; the urine sediment components are automatically separated without centrifugation, so that the completeness of urine cells is ensured, and the damage of urine centrifugation to the cells and other visible components is prevented.

The invention discloses a heterocycle-pyrazole amine derivative and a preparation method and application thereof in resisting mycobacterium tuberculosis infection, the structure of the heterocycle-pyrazole amine derivative is shown as a formula I or a formula II, and R1, R2, R3, V, W, X, Y, Z and L are defined as the specification and the claims. Experiments prove that the heterocyclic-pyrazolamine derivative provided by the invention has obvious anti-mycobacterium tuberculosis activity, and is especially suitable for preparing drugs for preventing and / or treating related diseases caused by mycobacterium tuberculosis. # imgabs0 #

The present application relates to the technical field of mass spectrometry detection, and specifically discloses a method for screening tuberculosis-resistant substances based on mass spectrometry detection, which divides tuberculosis culture samples into a control group and a drug-treated group, extracts samples at different time points and performs rapid mass spectrometry detection to obtain multi-stage original mass spectrometry data. It is converted into structured visual coding features through feature extraction to reflect the specific response pattern of the strain under the action of drugs. In order to eliminate the baseline fluctuation interference caused by non-drug factors, a baseline fluctuation semantic correction strategy is introduced to quantify the systematic fluctuations based on the time change of the control group, and perform feature domain correction on the drug-treated group data, thereby stripping off background noise and highlighting the real drug response signal. Finally, the corrected features are used to distinguish the drug resistance category and output the confidence level, thereby improving the detection accuracy and reliability and providing a more solid technical support for the assessment of drug resistance.

The invention relates to the technical field of biological detection and medical diagnosis, and discloses a method capable of rapidly detecting mycobacterium tuberculosis, which comprises the following steps: S1, providing a detection test strip which sequentially comprises a sample pad, a combination pad, a chromatography membrane and a water absorption pad; wherein the combination pad is coated with a labeled mycobacterium tuberculosis specific nucleic acid probe, the chromatography membrane is provided with a detection line and a quality control line, capture molecules are fixed on the detection line and the quality control line, the method integrates a nucleic acid probe chromatography technology and simple sample treatment, expensive instruments are not needed, and a result can be obtained by visual inspection within 15 minutes. The kit remarkably reduces the detection threshold and cost, is simple and convenient to operate and high in sensitivity, can synchronously identify drug resistance, perfectly meets the urgent demand of primary medical scenes on rapid and accurate diagnosis of tuberculosis, and assists in early intervention and epidemic prevention and control.

The present invention discloses a recombinant antigen of Mycobacterium tuberculosis and a tuberculosis vaccine AEC based on this antigen, belonging to the technical field of biomedicine. In the present invention, the dominant antigen genes Rv1886c, Rv3875 and Rv0580c of three Mycobacterium tuberculosis are fused together to construct a new recombinant antigen of Mycobacterium tuberculosis, and a novel tuberculosis protein vaccine AEC containing three antigens is prepared based on this recombinant antigen. This vaccine can target multiple antigens of Mycobacterium tuberculosis, and the fusion of the three antigens Rv1886c, Rv3875 and Rv0580c can achieve better anti-tuberculosis immune protection. At the same time, the vaccine prepared in the present invention has a clear composition, a simple structure, is safe and specific, has higher safety advantages, and can be produced in a standardized manner, which is conducive to industrialization.

The invention discloses a mycobacterium tuberculosis gene rapid screening service system oriented to a health physical examination center, and relates to the technical field of health services, and the mycobacterium tuberculosis gene rapid screening service system is characterized in that a sample is subjected to automatic uniform mixing and transfer to complete standardized pretreatment; the mechanical arm accurately loads the preprocessed sample to each independent channel of the micro-fluidic chip; bacterial lysis, nucleic acid adsorption, washing and elution are automatically completed in the sealed chip; the channels of the chip are subjected to thermal cycle amplification in parallel and generate target specific fluorescence signals; the system collects fluorescence intensity data of each channel in real time and automatically completes filtering and normalization processing; the trained deep learning model automatically analyzes a fluorescence curve and classifies results; and the system automatically generates an encrypted report and distributes the encrypted report to a subject and a health management center. By integrating closed parallel processing of the multi-channel micro-fluidic chip and fluorescence curve automatic analysis based on deep learning, automation and intelligentization of the whole process from sample loading to report generation can be realized.

The utility model relates to medical detection equipment technical field discloses a kind of mixing device based on tubercle bacillus drug sensitive detection, including storage bucket, the upper portion of the storage bucket is provided with sealing mechanism, the inside of the storage bucket is provided with storage mechanism, the storage mechanism includes motor, the bottom of the motor is fixedly installed in the inside bottom middle portion of storage bucket, the top of the motor is fixedly connected with the shaft of a steam turbine.The utility model drives the rotation of placing disc by bottom motor shaft, and stable mechanical power output can realize the efficient mixing of rotating sample and diluent, centrifugal force and eddy current effect are generated in rotation to promote liquid layering, accelerate uniform mixing, and motor speed is controllable, avoid traditional method to shake unevenly, shorten mixing time, directly reduce drug sensitive detection period, further applicable to high-throughput experimental environment, can support batch processing sample, also can integrate full-automatic detection system, reduce manual intervention, reach laboratory intelligent trend.

The invention relates to a medical sample collection instrument, and discloses a mycobacterium tuberculosis nucleic acid detection sputum sample collection device which comprises a collection pipe, a filter membrane is arranged in the collection pipe, a sealing mechanism is installed at the top of the collection pipe, an extraction mechanism is slidably connected to the top of the sealing mechanism, and the sealing mechanism comprises an opening and closing assembly. The opening and closing assembly comprises a cam disc and a pin shaft, an arc-shaped groove position is formed in the surface of the cam disc, the pin shaft is slidably connected to the inner wall of the inner arc-shaped groove position, a baffle is fixedly connected to the bottom of the pin shaft, a chassis is slidably connected to the bottom of the baffle, a sliding rail is arranged on the surface of the top of the chassis, and the baffle moves along the sliding rail. By means of the arc-shaped groove position structure on the surface of the cam disc, the traction pin shaft slides synchronously, then the baffle is driven to move front and back along the sliding rail at the bottom of the chassis, operation steps are greatly simplified, loading and taking out of samples can be completed more efficiently, and convenience of clinical operation is remarkably improved.

The invention provides a method for detecting the protein content according to the color of a TB-PPD-producing mycobacterium tuberculosis culture filtrate, which is characterized in that a correlation model between color parameters of a mycobacterium tuberculosis culture and the protein content is established through statistical analysis to calculate the protein content in the culture filtrate. The color parameter of the mycobacterium tuberculosis culture is a red (R) color value or a gray value. According to the method, opening sampling detection is not needed, a non-destructive and on-line rapid evaluation reference tool is provided for quality control in the TB-PPD production process, the sterility risk caused by bottle opening detection is reduced, and the production efficiency is improved.

The invention relates to the technical field of pathology, in particular to a combined strain cell positive control wax block and a preparation method thereof. The preparation method comprises the following steps: strain samples are placed in an inactivation stationary liquid for inactivation treatment to obtain an inactivated strain suspension, the strain samples comprise aspergillus, cryptococcus, talaromyces marneffei and mycobacterium tuberculosis, and the inactivation stationary liquid comprises ethanol and a formaldehyde solution; carrying out centrifugal treatment on the inactivated strain suspension to obtain a precipitate, dissolving the precipitate in an agar solution, and then carrying out solidification treatment to obtain an agar block wrapping the inactivated strain; and sequentially carrying out dehydration treatment and embedding treatment on the agar block to obtain the combined strain cell positive control wax block. According to the method, a large number of positive control wax blocks of various fungi and mycobacterium tuberculosis cells can be rapidly manufactured, the positive bacteria are more, the background is clear, interference is little, misjudgment is not easily caused, positive bacteria can be rapidly observed, and the method can be widely applied to positive control of various morphological experiments.

The present invention provides a tuberculosis subunit vaccine, which comprises natural polysaccharides extracted from Mycobacterium tuberculosis, and comprises one, more or all of the proteins ESAT6, Ag85b, HspX, Rv1738 and Rv2626; and is combined with aluminum adjuvant and polyIC. The polysaccharides extracted from Mycobacterium tuberculosis have both antigenic and adjuvant functions; ESAT6, Ag85b, HspX, Rv1738 and Rv2626 cover highly antigenic tuberculosis proteins and antigenic proteins for latent infection, enabling the vaccine to not only prevent Mycobacterium tuberculosis infection but also prevent tuberculosis in infected individuals, playing a role in preventive treatment.

This invention relates to a class of heterocyclic ethylenediazine hexamolybdate tetrabutylammonium derivatives, their preparation methods, and applications, with the chemical formula: (n-Bu4N)3[Mo6O 18 [=N=NCO-HC]; where HC represents pyridinyl, thiophene, furanyl, or pyrazinyl, and n-Bu represents n-butyl; the preparation method includes the following steps: refluxing an organic ligand, a dehydrating agent, and tetrabutylammonium octamolybdate in an organic solvent, wherein the organic ligand is a heterocyclic hydrazide; after reflux, a heterocyclic ethylenediazene hexamolybdate tetrabutylammonium derivative is obtained by separation. This invention utilizes a heterocyclic hydrazide to covalently modify a hexamolybdate cluster, and the resulting heterocyclic ethylenediazene hexamolybdate tetrabutylammonium derivative exhibits certain inhibitory activity against Mycobacterium tuberculosis.

The invention provides a genetically modified tubercle bacillus strain as well as a preparation method and application thereof, the strain is tubercle bacillus obtained by knocking out virulence-related genes by adopting a genetic engineering method and simultaneously supplementing and enhancing immunogenicity antigen genes, and can be used for preparing attenuated live vaccines. The attenuated live vaccine prepared by using the strain has lower adverse reaction rate and stronger immunogenicity, and can be used for replacing a bacillus calmette guerin vaccine or a booster vaccine. Moreover, the DTH reaction caused by vaccination or infection can be identified through TBST (based on Mycobacterium tuberculosis antigen skin test) by using the vaccine prepared by the strain, and the strain has important application in tuberculosis vaccine production.

The invention discloses a guaiane type sesquiterpene compound as well as a preparation method and application thereof, and belongs to the technical field of chemical medicines. The invention provides a guaiane type sesquiterpene compound with a novel structure, which is extracted from lactarius deliciosus sporocarp, can well inhibit the activity of mycobacterium tuberculosis, especially has an excellent inhibition effect on single-drug-resistant mycobacterium tuberculosis and multi-drug-resistant mycobacterium tuberculosis, and can be used for preparing medicines for treating lactarius deliciosus. The guaiane type sesquiterpene compound is expected to be used for treating tuberculosis, especially drug-resistant tuberculosis, so that the variety of drugs for treating tuberculosis, especially drug-resistant tuberculosis, is expanded, and the application range of lactarius deliciosus extract is also expanded.

A method for diagnosing Mycobacterium tuberculosis according to an embodiment comprises the steps of: preparing a first diagnosis model trained for diagnosis of Mycobacterium tuberculosis classified as exhibiting normal growth; preparing a second diagnosis model trained for diagnosis of Mycobacterium tuberculosis classified as being affected by a cocktail containing antibiotics; preparing a third diagnosis model trained for diagnosis of other bacteria similar in shape to the Mycobacterium tuberculosis at or above a predetermined level without being affected by the antibiotics; and deriving a diagnosis result of Mycobacterium tuberculosis for a specimen by using a result of diagnosing the specimen acquired through a camera by at least one of the first diagnosis model, the second diagnosis model, and the third diagnosis model.